Wedmont Private Capital Purchases 938 Shares of McKesson Corporation $MCK

Posted by George Bondi on Oct 10th, 2026

Wedmont Private Capital grew its holdings in shares of McKesson Corporation (NYSE:MCK – Free Report) by 36.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,494 shares of the company’s stock after acquiring an additional 938 shares during the quarter. Wedmont Private Capital’s holdings in McKesson were worth $3,250,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in McKesson during the 2nd quarter valued at $8,156,743,000. State Street Corp boosted its position in McKesson by 0.5% during the 4th quarter. State Street Corp now owns 5,780,179 shares of the company’s stock valued at $4,746,118,000 after acquiring an additional 29,660 shares in the last quarter. Bank of America Corp DE boosted its position in shares of McKesson by 2.4% during the first quarter. Bank of America Corp DE now owns 1,538,726 shares of the company’s stock valued at $1,331,552,000 after purchasing an additional 35,916 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of McKesson by 6.8% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,376,276 shares of the company’s stock valued at $1,128,945,000 after buying an additional 87,513 shares in the last quarter. Finally, Swedbank AB boosted its stake in McKesson by 13.5% during the first quarter. Swedbank AB now owns 1,005,610 shares of the company’s stock worth $870,215,000 after acquiring an additional 119,327 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling

In other news, CAO B Jr sold 111 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the sale, the chief accounting officer directly owned 521 shares of the company’s stock, valued at $464,445.45. This trade represents a 17.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

MCK has been the topic of several analyst reports. TD Cowen boosted their target price on McKesson from $989.00 to $1,006.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Mizuho lifted their target price on shares of McKesson from $885.00 to $905.00 in a research report on Thursday, August 6th. Evercore reaffirmed an “outperform” rating and set a $950.00 price target (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Wells Fargo & Company boosted their price objective on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a $845.00 price objective on shares of McKesson in a research note on Monday, September 14th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $983.29.

Read Our Latest Analysis on McKesson

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

Positive Sentiment: Analysts raised their outlook. Barclays increased its price target to $1,000, and Leerink Partners initiated or reiterated a Buy rating, reinforcing the view that McKesson can continue to appreciate. McKesson also carries a consensus “Moderate Buy” recommendation. Barclays raised its target for McKesson stock to USD 1,000.00
Positive Sentiment: McKesson is expanding its specialty healthcare business. The company is partnering with Clayton, Dubilier & Rice to acquire Option Care Health in a transaction valued at approximately $5.8 billion, including debt. The deal would give McKesson greater exposure to home and alternate-site infusion services, potentially adding growth and strategic diversification. McKesson, CD&R to Acquire Option Care Health
Neutral Sentiment: The acquisition’s valuation is attracting investor scrutiny. Option Care shareholders are being offered $32.05 per share, a 37% premium, which could accelerate growth but also raises questions about price, financing, execution and integration risks. McKesson Joins $5.8 Billion Option Care Health Acquisition
Positive Sentiment: Momentum and fundamental screens remain favorable. Zacks highlighted McKesson as a long-term momentum and growth stock, while Wall Street’s average recommendation remains bullish. Its latest reported quarter also exceeded expectations, with EPS of $9.93 and revenue of $105.38 billion.
Neutral Sentiment: Long-term-return coverage provides context rather than a new catalyst. A review of a decade-long investment illustrates McKesson’s strong historical performance, but it does not directly change current earnings or valuation expectations. If You Invested $1000 in McKesson a Decade Ago

McKesson Price Performance

NYSE:MCK opened at $937.65 on Friday. The company has a market cap of $109.32 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 1.95 and a beta of 0.30. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $999.00. The stock’s 50 day simple moving average is $885.20 and its two-hundred day simple moving average is $833.76.

McKesson (NYSE:MCK – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The firm had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. McKesson’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period last year, the firm posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, analysts anticipate that McKesson Corporation will post 44.73 EPS for the current year.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were given a $0.94 dividend. This is an increase from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date was Tuesday, September 1st. McKesson’s dividend payout ratio (DPR) is 10.06%.

McKesson Profile

(Free Report)

McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.

McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.